Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett, Shaun G Goodman, Ronald M Goldenberg, Mohammed Al-Omran, Richard E Gilbert, Deepak L Bhatt, Lawrence A Leiter, Peter Juni, Bernard Zinman, Kim A Connelly
Circulation | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim to Drs Verma and Zinman. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or decision to submit the manuscript for publication. The database for the study was located, and the data analyses were conducted, at the not-for-profit academic research organization Applied Health Research Centre (AHRC), which is integrated with the Li Ka Shing Knowledge Institute of St. Michael's Hospital, and not shared with the funder. The manuscript was modified after consultation with the co-authors. The authors had unrestricted rights to publish the results and the final decision on content was exclusively retained by the authors.